Reagila, developed in Hungary, Medicine of the Year

Richter's atypical antipsychotic, Reagila, containing the active ingredient cariprazine, was awarded the title of Drug of the Year 2019 by the Hungarian Society for Experimental and Clinical Pharmacology (HUNPHAR).

Each year, the prestigious award recognizes the most advanced and effective products that have made a significant breakthrough in the cure of a disease. The award was received by Erik Bogsch, Chairman of the Board of Gedeon Richter Plc. from Dr. Péter Ferdinandy, the President of HUNPHAR,

Cariprazine is an original atypical antipsychotic developed in Hungary, which was granted a marketing authorization in the United States under the brand name Vraylar in 2015 for the treatment of manic or mixed episodes associated with schizophrenia and type I bipolar disorder, and in 2019 for bipolar depression. In 2017, it received a pedigree license valid for 28 member states of the European Union under the brand name Reagila for the treatment of schizophrenia.

The Jury, whose members were asked by the management of HUNPHAR to participate, recommended Reagila to award the title of Drug of the Year 2019 primarily due to its special impact and added value in domestic research and development. It is on the basis of the Jury's proposal that the management of HUNPHAR and the General Assembly decides secret ballot.

Dr. Péter Ferdinandy, President of the Hungarian Society for Experimental and Clinical Pharmacology, Vice-Chancellor of Science and Innovation at Semmelweis University, emphasized at the awards ceremony at Semmelweis University that “cariprazine is a drug with a unique spectrum of action, whose effectiveness not only been demonstrated in clinical trials in the treatment of schizophrenia, but also in that of acute manic, acute depressive, and acute mixed episodes of bipolar disorder, and the spectrum of side effects is also very favorable. For many years, cariprazine has been the first truly Hungarian drug, the discovery and development of which is linked to the researchers of Richter Gedeon Plc. In a few years, the product has entered the practice of patient care worldwide, it is expected to have a great future and it has rightly earned the title of Medicine of the Year in Hungary. "